Navigation Links
Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
Date:9/16/2009

BERLIN, Sept. 17 /PRNewswire/ -- Bayer HealthCare today announced that data from more than 30 clinical trials evaluating three products in the company's oncology portfolio - Nexavar(R) (sorafenib) tablets, regorafenib (BAY 73-4506) and Alpharadin(TM) - will be presented at the joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress, September 20-24, 2009 in Berlin, Germany.

"Bayer is committed to discovering and developing innovative cancer-fighting therapies, and as a global organization with widespread reach and impact, we are able to apply our experience, knowledge and passion to offer treatments that may make life better for cancer patients across the globe," said Rob Rosen, Head of the Therapeutic Area Oncology at Bayer HealthCare. "While much progress has been made in the treatment of cancer, there is still an unmet medical need for improved therapies that may help patients manage their disease, ultimately treating cancer as a chronic illness, rather than a devastating disease."

Nexavar Data Highlights

Nexavar is currently approved in more than 80 countries for the treatment of patients with hepatocellular carcinoma (HCC), or liver cancer, and in more than 90 countries for the treatment of patients with advanced renal cell carcinoma (RCC), or kidney cancer. Even though these indications are well established, the utility of Nexavar continues to be evaluated in these tumor types, with ongoing studies examining special patient populations and long-term use. Data on these indications being presented at ECCO-ESMO include results from two Phase III studies evaluating Nexavar in HCC and six studies examining Nexavar in RCC.

In addition to its current indications, Nexavar continues to be evaluated as a single agent or combination treatment in a wide range of cancers, including
'/>"/>

SOURCE Bayer HealthCare
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
2. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
3. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
4. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
5. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
6. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
7. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
8. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
9. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
10. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
11. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , Sept. 22, 2014 ... of the "Global Ablation Technologies (Radiofrequency, Ultrasound, ... 2019" report to their offering. ... the global ablation technologies market has been divided ... ultrasound, microwave, cryotherapy, hydrothermal, and hydromechanical ablation technologies. ...
(Date:9/22/2014)... - T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company"), ... marijuana products, is pleased to announce that its wholly ... definitive lease agreement for a second facility located in ... 28,966 square feet of floor space with the option ... for a total of approximately 43,500 square feet. ...
(Date:9/22/2014)... Pa. , Sept. 22, 2014  Olympus, ... innovative solutions for medical and surgical procedures, among ... a deal with Munich -based ... Kick ® Navigation. This agreement applies to ... for cross-disciplinary U.S. sales and all distribution outside ...
Breaking Medicine Technology:Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 2Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 3T-Bird Pharma Inc. to Increase Growing Capacity with Expansion into a 43,500 square feet Second Facility 2T-Bird Pharma Inc. to Increase Growing Capacity with Expansion into a 43,500 square feet Second Facility 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 4
... 26 New Health Sciences Inc. (NHSi) has ... National Heart, Lung and Blood Institute of the National ... system. The project aims to develop the Hemanext ... transfusion therapy and extends the shelf life of blood ...
... ("Senesco" or the "Company") (NYSE Amex: SNT ) ... conducted in Dr. William Scheld,s lab at the University of ... against Senesco,s Factor 5A gene had a 52% survival rate as ... treatment or a control siRNA.A total of 73 mice were infected ...
Cached Medicine Technology:Bethesda-Based NHSi Wins $2M Grant for Blood Technology 2Bethesda-Based NHSi Wins $2M Grant for Blood Technology 3Senesco Announces H1N1 Influenza Survival Test Results in Mice 2Senesco Announces H1N1 Influenza Survival Test Results in Mice 3
(Date:9/22/2014)... ARBOR, Mich. A surprising new study pulls back ... in health care: differences in payment and income between ... who don,t. , Contrary to perception, the research ... to favor surgeons and other procedure-performing doctors. , The ... simple difference in pay per minute explains why doctors ...
(Date:9/22/2014)... HealthDay Reporter MONDAY, Sept. ... parents are aware of online physician-rating sites, and more than ... children, according to a new national study. The findings ... further suggest that negative online ratings may dissuade parents from ... by a neighbor. Conversely, a positive online rating may ...
(Date:9/22/2014)... (September 22, 2014) South Asians living in Canada ... the rate of diabetes compared with while people, McMaster ... today in the Canadian Medical Association Journal (CMAJ ... , One of the fastest-growing ethnic groups in ... Asian people living in Canada, comprising about three percent ...
(Date:9/22/2014)... September 22, 2014. Kessler researchers have published a ... psychoeducational wellness program in people with multiple sclerosis ... mental health, perceived stress, and pain. "Development ... individuals living with MS: Description and outcomes" was ... the International Journal of MS Care ...
(Date:9/22/2014)... Two new prescription devices approved by the U.S. Food ... people with migraine headaches who don,t tolerate migraine medications ... -- the Cefaly -- is designed to prevent migraines, ... meant to be used when migraines first start, according ... looking for alternative migraine treatments. Because these devices aren,t ...
Breaking Medicine News(10 mins):Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 2Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 4Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 2Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 3Health News:Higher risk of heart disease for South Asians in Canada 2Health News:Noninvasive Devices May Help Migraines, FDA Says 2
... Massachusetts Medical School have uncovered a novel DNA-sensing pathway ... for malaria. Activation of this pathway appears to stimulate ... immune system that may contribute to inflammation and fever ... susceptibility for the most common and lethal form of ...
... Calif.) The possibility of developing stem cells from ... conditions as diverse as Parkinson,s disease, Alzheimer,s disease and ... research community in recent years. Such therapies would avoid ... human embryos, and in theory, also bypass immunological problems ...
... heart contains cardiac stem cells that can contribute to regeneration ... about the molecules and pathways that regulate these cells. Now, ... insight into one way to coax the cardiac stem cells ... Press in the August 2011 issue of the journal ...
... Companies like Google and Zappos.com are famous for ... environments, but are their employees healthier too? According to ... your co-workers has long-term health benefits. Dr. ... TAU,s Leon Recanati Graduate School of Business Administration says ...
... Denise Mann HealthDay Reporter , THURSDAY, Aug. 4 ... harnessing the power of stem cells to help treat, and ... in a recent issue of the Journal of the ... be reprogrammed to morph into other types of kidney cells ...
... Medical Sciences of the National Institutes of Health (NIH) ... million to support the Wayne State University Initiative for ... established in 1978 as the Minority Biomedical Research Support ... graduate students with a more personalized experience to foster ...
Cached Medicine News:Health News:Targeting innate immunity in malaria 2Health News:Targeting innate immunity in malaria 3Health News:A patient's own skin cells may one day treat multiple diseases 2Health News:A patient's own skin cells may one day treat multiple diseases 3Health News:Hormone reduces risk of heart failure from chemotherapy 2Health News:Hang out at the water cooler, live longer 2Health News:Hang out at the water cooler, live longer 3Health News:Stem Cell Therapy Holds Promise for Kidney Disease 2Health News:Stem Cell Therapy Holds Promise for Kidney Disease 3Health News:Wayne State University awarded $3 million from NIH to foster science and research careers 2Health News:Wayne State University awarded $3 million from NIH to foster science and research careers 3
... Preserve your data for future generations. Most gels ... solid backing plate of our gel dryer, covering ... frame over them to hold the cellophane flat. ... frame with an open area somewhat larger than ...
... for future generations. Most gels can be dried ... of our gel dryer, covering them with wet ... to hold the cellophane flat. Tut's Tombs also ... open area somewhat larger than the gel to ...
... Slim Slab Gel Dryer accommodates large sequencing gels or ... TEFLON coated platen for long lasting durability and corrosion ... , Quick Drying Rate - large ... , Digital display of temperature and time ...
... gel dryer and oil-free vacuum pump into one ... setup. The extremely versatile gel drying system can ... and multiple mini-gels as well as drying large ... Completely Integrated Gel Drying System eliminates setup ...
Medicine Products: